Kanglaite injection, an anti- cancer Chinese traditional herbal medicine, has been approved by the Food and Drug Administration of the United States to be used for clinical human experiment, according to sources with the State Administration of Traditional Chinese Medicine.

This is the first time that a traditional Chinese medicine has been approved for clinic experiment in the U.S., the sources said, claiming it a new step towards the global drug market.

Kanglaite injection is developed from liquid distilled from the seeds of Job's tears, which is a kind of herbal medicine.

It is targeted to effectively kill cancer cells while upgrading the immune capacity of the human body.

In China, the medicine has been used in thousands of clinical experiments and by more than 200,000 tumor patients. The results show that the medicine is effective in its anti-cancer actions and has no apparent side effects.

The active compound, production techniques and prescriptions of the medicine have received patent certificates in countries such as the U.S., Japan and European Union.
The medicine enjoys the largest sales volume among Western and traditional Chinese anti-cancer medicines in China.